• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Twelve-year continuous therapy with vismodegib for advanced basal cell carcinoma: Tolerability and partial reversibility of adverse events.

作者信息

Cortes Marianne, Grubbs Hailey, Strasswimmer John

机构信息

Nova Southeastern University Kiran C Patel College of Osteopathic Medicine, Davie, Florida.

Dermatology Department, Broward Health Medical Center, Fort Lauderdale, Florida.

出版信息

JAAD Case Rep. 2024 May 14;64:7-9. doi: 10.1016/j.jdcr.2024.05.004. eCollection 2025 Oct.

DOI:10.1016/j.jdcr.2024.05.004
PMID:40918548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12410498/
Abstract
摘要

相似文献

1
Twelve-year continuous therapy with vismodegib for advanced basal cell carcinoma: Tolerability and partial reversibility of adverse events.维莫德吉用于晚期基底细胞癌的12年持续治疗：不良事件的耐受性和部分可逆性
JAAD Case Rep. 2024 May 14;64:7-9. doi: 10.1016/j.jdcr.2024.05.004. eCollection 2025 Oct.
2
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.诱导治疗联合维莫德吉与根治性放疗治疗局部晚期不可切除基底细胞癌的 II 期单臂试验。
J Clin Oncol. 2024 Jul 1;42(19):2327-2335. doi: 10.1200/JCO.23.01708. Epub 2024 Apr 17.
3
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.晚期基底细胞癌患者接受 Hedgehog 通路抑制剂维莫德吉治疗的扩大准入研究。
J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1.
4
Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.Hedgehog 通路抑制剂治疗局部晚期和转移性基底细胞癌：干预性研究的系统评价和汇总分析。
JAMA Dermatol. 2016 Jul 1;152(7):816-24. doi: 10.1001/jamadermatol.2016.0780.
5
Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.探索维莫德吉：一种治疗眼部晚期基底细胞癌的非手术突破。
Cancer Treat Res Commun. 2024;39:100796. doi: 10.1016/j.ctarc.2024.100796. Epub 2024 Feb 14.
6
Alternate Dosing Regimens for Vismodegib: A Literature Review.
Curr Treat Options Oncol. 2025 Jul;26(7):587-591. doi: 10.1007/s11864-025-01332-6. Epub 2025 May 26.
7
Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.维莫德吉治疗斯洛文尼亚局部晚期基底细胞癌。
Dermatology. 2023;239(1):158-164. doi: 10.1159/000525612. Epub 2022 Jul 27.
8
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome.维莫德吉对两名转移性基底细胞癌和基底细胞痣综合征患者的长期安全性、耐受性及疗效
Dermatol Reports. 2011 Dec 1;3(3):e55. doi: 10.4081/dr.2011.e55. eCollection 2011 Oct 5.
9
Secondary cutaneous malignancy after treatment of basal cell carcinoma with hedgehog pathway inhibitor: a systematic review.治疗基底细胞癌的 Hedgehog 通路抑制剂后继发皮肤第二恶性肿瘤：系统评价。
Arch Dermatol Res. 2024 Oct 26;316(10):716. doi: 10.1007/s00403-024-03471-6.
10
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.基底细胞痣综合征患者中 hedgehog 通路的抑制：多中心、随机、双盲、安慰剂对照、2 期临床试验的最终结果。
Lancet Oncol. 2016 Dec;17(12):1720-1731. doi: 10.1016/S1470-2045(16)30566-6. Epub 2016 Nov 10.

本文引用的文献

1
Optimizing the pharmacokinetics of sonidegib in small bowel syndrome and advanced basal cell carcinoma: Our solution.优化索纳替尼在小肠综合征和晚期基底细胞癌中的药代动力学：我们的解决方案。
JAAD Case Rep. 2023 Jun 20;38:152-154. doi: 10.1016/j.jdcr.2023.06.016. eCollection 2023 Aug.
2
Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives.晚期基底细胞癌的长期管理：当前挑战与未来展望
Cancers (Basel). 2022 Sep 20;14(19):4547. doi: 10.3390/cancers14194547.
3
Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.
荷兰晚期和多发性基底细胞癌患者使用维莫德吉的 8 年经验：一项回顾性队列研究。
Br J Cancer. 2021 Mar;124(7):1199-1206. doi: 10.1038/s41416-020-01220-w. Epub 2021 Jan 19.
4
Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy.维莫德吉治疗基底细胞癌的聚焦：对其在治疗中地位的循证综述
Clin Cosmet Investig Dermatol. 2017 May 10;10:171-177. doi: 10.2147/CCID.S101330. eCollection 2017.
5
Spontaneous resolution of advanced basal cell carcinoma after short-pulse treatment with hedgehog pathway inhibitor.经刺猬信号通路抑制剂短脉冲治疗后晚期基底细胞癌的自发消退
JAAD Case Rep. 2016 Aug 30;2(4):360-1. doi: 10.1016/j.jdcr.2016.06.010. eCollection 2016 Jul.
6
Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.维莫德吉治疗基底细胞痣综合征患者的安全性和有效性：两项试验的汇总分析
Orphanet J Rare Dis. 2016 Sep 1;11(1):120. doi: 10.1186/s13023-016-0506-z.
7
Four-year experience with vismodegib hedgehog inhibitor therapy.维莫德吉（vismodegib）刺猬因子抑制剂治疗的四年经验
J Am Acad Dermatol. 2016 Jun;74(6):1264-5. doi: 10.1016/j.jaad.2015.12.035.
8
Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.Hedgehog 通路抑制剂治疗局部晚期和转移性基底细胞癌：干预性研究的系统评价和汇总分析。
JAMA Dermatol. 2016 Jul 1;152(7):816-24. doi: 10.1001/jamadermatol.2016.0780.
9
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.维莫德吉治疗晚期基底细胞癌的疗效和安全性。
N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713.